CDK4 and non-small cell lung carcinoma: Given the preclinical benefits of CDK4/6 inhibitors in molecularly selected subsets, CDK4/6 inhibitors may have another role in the treatment of NSCLC in selected populations based on reasonable biomarkers, combined with radiotherapy and other agents, including growth factor pathway inhibitors and immune checkpoint inhibitors.